期刊文献+

Drug resistance and combating drug resistance in cancer 被引量:21

原文传递
导出
摘要 Cancer is the second leading cause of death in the US.Current major treatments for cancer management include surgery,cytotoxic chemotherapy,targeted therapy,radiation therapy,endocrine therapy and immunotherapy.Despite the endeavors and achievements made in treating cancers during the past decades,resistance to classical chemotherapeutic agents and/or novel targeted drugs continues to be a major problem in cancer therapies.Drug resistance,either existing before treatment(intrinsic)or generated after therapy(acquired),is responsible for most relapses of cancer,one of the major causes of death of the disease.Heterogeneity among patients and tumors,and the versatility of cancer to circumvent therapies make drug resistance more challenging to deal with.Better understanding the mechanisms of drug resistance is required to provide guidance to future cancer treatment and achieve better outcomes.In this review,intrinsic and acquired resistance will be discussed.In addition,new discoveries in mechanisms of drug resistance will be reviewed.Particularly,we will highlight roles of ATP in drug resistance by discussing recent findings of exceptionally high levels of intratumoral extracellular ATP as well as intracellular ATP internalized from extracellular environment.The complexity of drug resistance development suggests that combinational and personalized therapies,which should take ATP into consideration,might provide better strategies and improved efficacy for fighting drug resistance in cancer.
出处 《Cancer Drug Resistance》 2019年第2期141-160,共20页 癌症耐药(英文)
  • 相关文献

参考文献5

二级参考文献64

  • 1张阿丽,王全胜,钟亚华,陈刚,奚玲,谢从华,周云峰,马丁.转录因子Snail调控上皮-间质转型及对肿瘤转移的逆转作用[J].癌症,2005,24(11):1301-1305. 被引量:11
  • 2Min Sun Kim,Young Jin Park.Detection and treatment of synchronous lesions in colorectal cancer: The clinical implication of perioperative colonoscopy[J].World Journal of Gastroenterology,2007,13(30):4108-4111. 被引量:10
  • 3Rowley JD.A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.Nature,1973,243:290-293.
  • 4Goldman JM,Melo JV.Chronic myeloid leukemia-advances in biology and new approaches to treatment.N Engl J Med,2003,349:1451-1464.
  • 5Hehlmann R,Hochhus A,Baccarani M.Chronic myeloid leukemia.Lancet,2007,370:342-350.
  • 6Roskoski R Jr.STI-571:an anticancer protein-tyrosine kinase inhibitor.Biochem Biophys Res Commun,2003,309:709-717.
  • 7Walz C,Sattler M.Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia(CML).Crit Rev Oncol Hematol,2006,57:145-164.
  • 8Sawyers CL.Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.Cancer Cell,2002,1:13-15.
  • 9Shah NP,Sawyers CL.Mechanisms of resistance to STI571in Philadelphia chromosome-associated leukemias.Oncogene,2003,22:7389-7395.
  • 10Druker BJ,Tamura S,Buchdunger E,et al.Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med,1996,2:561-566.

共引文献54

同被引文献57

引证文献21

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部